阻断新生儿Fc受体预防心脏型新生儿狼疮的概念验证研究
一例34岁系统性红斑狼疮孕妇,既往3次妊娠均并发新生儿狼疮(含1次20周致死性心脏型),本次妊娠14至28周每周皮下注射560 mg rozanolixizumab。孕22周母体抗SSA/Ro52及Ro60抗体、总IgG及IgG1-3亚类下降约65%,孕34周恢复至接近基线;37周顺产健康新生儿,新生儿5周出现新生儿狼疮皮疹,无严重不良事件。
要点
- 孕14至28周每周皮下注射560 mg rozanolixizumab,孕22周母体抗SSA/Ro52、Ro60抗体及总IgG、IgG1-3亚类下降约65%。
- 37周顺产健康新生儿,脐血及母体IgG水平正常,无需静脉免疫球蛋白补救。
- 新生儿超声心动图及心电图正常,但5周龄出现符合新生儿狼疮的皮疹,无严重不良事件。
核心结论
- FcRn阻断成功预防复发性心脏型新生儿狼疮,为多中心研究提供先例。
研究设计与样本
- 一例34岁系统性红斑狼疮孕妇,既往3次连续妊娠均并发新生儿狼疮(1次皮肤型、1次20周致死性心脏型、1次32周分娩心脏型并新生儿皮肤型),均使用羟氯喹400 mg/日。
- 通过同情用药,自孕14周至28周每周皮下输注560 mg rozanolixizumab(抗FcRn人源化IgG4单克隆抗体)。
- 患者每日3次居家胎心监测,每周超声心动图检查。
主要发现
- 孕22周母体抗SSA/Ro52及Ro60抗体、总IgG及IgG1、2、3亚类下降约65%,孕34周恢复至接近基线水平。
- 妊娠过程无并发症,37周自然阴道分娩健康新生儿。
- 分娩时脐血及母体IgG水平正常,无需静脉免疫球蛋白补救。
- 新生儿超声心动图及心电图正常,但5周龄出现符合新生儿狼疮的皮疹。
- 无严重不良事件。
关键数值与推荐
- rozanolixizumab 560 mg每周皮下注射,孕14至28周给药。
- 母体抗SSA/Ro52及Ro60抗体、总IgG及IgG1、2、3亚类在孕22周下降约65%,孕34周恢复至接近基线。
临床怎么用
- 对高滴度抗SSA/Ro52或Ro60抗体孕妇,FcRn阻断可能通过降低血清IgG及抑制胎盘转运预防心脏型新生儿狼疮。
- 孕14至28周给药覆盖胎儿心脏损伤易感期,需配合胎心监测及超声心动图。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Novel biologic agents targeting the neonatal Fc receptor (FcRn) offer a promising strategy to prevent cardiac neonatal lupus (cardiac-NL) in pregnant patients with high-titre anti-SSA/Ro52 kD or 60 kD autoantibodies via dual effects: reducing serum immunoglobin G (IgG) levels and inhibiting placental transfer. This study was initiated to assess the feasibility of FcRn blockade as prophylactic therapy for recurrent cardiac-NL. METHODS: A 34-year-old pregnant patient with systemic lupus erythematosus and 3 prior consecutive pregnancies complicated by neonatal lupus (1 cutaneous, 1 fatal cardiac-NL at 20 weeks, 1 cardiac-NL delivered at 32 weeks and neonatal cutaneous NL), each despite hydroxychloroquine 400 mg daily, was treated with weekly subcutaneous infusions of 560 mg rozanolixizumab (humanised IgG4 monoclonal antibody against FcRn) from gestational weeks 14 to 28 (to cover the vulnerable period of fetal cardiac injury) through a compassionate use designation. The patient performed home fetal heart rhythm monitoring thrice daily with weekly echocardiograms. RESULTS: Maternal anti-SSA/Ro52 kD and 60 kD autoantibodies, total IgG, and subclasses IgG1, 2, 3 decreased by about 65% at gestational week 22, with a return to near baseline levels by week 34. The pregnancy was uncomplicated, resulting in a spontaneous vaginal delivery of a healthy neonate at 37 weeks. At delivery, cord blood and maternal IgG levels were normal, obviating the need for rescue intravenous immune globulin. The neonate had a normal echocardiogram and electrocardiogram but developed a rash consistent with neonatal lupus at 5 weeks of life. There were no serious adverse events. CONCLUSIONS: The successful application of FcRn blockade to prevent recurrent cardiac-NL sets a precedent for a multicentre study.
引用
- Carlucci PM, Masson M, Cuneo BF, et al. Blocking the neonatal Fc receptor as a novel approach to prevent cardiac neonatal lupus: a proof-of-concept study. Ann Rheum Dis. 2025. PMID: 41111019. doi:10.1016/j.ard.2025.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。